The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B)

C. Angelini, L. Nardetto, C. Borsato, R. Padoan, M. Fanin, A. C. Nascimbeni, E. Tasca
  • Neurological Research, February 2010, Taylor & Francis
  • DOI: 10.1179/174313209x380847

This represents an accurate description of disease course in two main LGMD

What is it about?

Description of modulating factors in two common recessive LGMD shows progression of disease with time both for dysferlin deficiency and calpain deficiency and an early onset of disease in calpainopathy with complete loss of protein

Why is it important?

First study to investigate and compare two common LGMDs

Perspectives

Prof Corrado Angelini
IRCCS S.Camillo Hospital Foundation

Basis for clinical trials in LGMDs that are still missing a valid therapeutical approach.

Read Publication

http://dx.doi.org/10.1179/174313209x380847

The following have contributed to this page: Prof Corrado Angelini